LianBio - ADR
LIAN
Get informed when a big investor buys or sells
+ FollowMarket Cap$34.47M
Close$
$0.69
117.5% upside
Current Fair Value
117.5% upsideUndervalued by 117.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $34.47 Million |
|---|---|
| Enterprise Value | $-401,654,990.00 |
| Dividend Yield | $9.55 (-) |
| Earnings per Share | $-1.02 |
| Beta | 0.23 |
| Outstanding Shares | 107,167,691 |
Return
| Return on Equity | 54.03% |
|---|---|
| Return on Assets | 50.82% |
| Return on Invested Capital | 52.46% |
Valuation & Multiples
| P/E Ratio | 1.13 |
|---|---|
| PEG | -0.05 |
| Price to Sales | - |
| Price to Book Ratio | 0.06 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.32 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | -0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About LianBio
163 employees
CEO: Adam Leo Stone LianBio is a biopharmaceutical firm dedicated to advancing and marketing therapeutic agents across various critical health sectors, including cardiovascular disorders, oncology, ophthalmological conditions, and inflammatory ailments. Its...